Introduction {#Sec1}
============

Primary hyperparathyroidism (PHPT) is a rather common endocrinological disorder, the third most common endocrine disease after diabetes mellitus and thyroid disorders. It is characterized by one or more hyperfunctioning parathyroid glands \[[@CR1]\], due to parathyroid adenoma (in \> 80% of cases), multiple adenomas, parathyroid hyperplasia (about 15%) or parathyroid carcinoma (less than 1%) \[[@CR2]\], \[[@CR3]\]. People with mild PHPT are at increased risk of various comorbidities, such as nephrolithiasis, osteoporosis and fragility fractures. Surgical excision is usually a definitive treatment, though repeat surgery may be required in cases of recurrent or persistent hyperparathyroidism (fewer than 5% of patients) \[[@CR4]\].

PHPT may also be associated with a higher risk of cardiovascular disease and mortality \[[@CR5], [@CR6]\]. The related mortality risk seems to be lower in patients who undergo surgery than in those treated conservatively \[[@CR6]\]. A recent cost-effectiveness analysis on patients with non-localized PHPT showed that use of advanced imaging methods is more cost-effective than routine bilateral neck exploration \[[@CR6]\]. Based on this evidence, it becomes essential to employ appropriate methods capable of revealing which parathyroid glands are causing PHPT. This is also important to avoid unnecessary surgery and to identify ectopic parathyroid glands.

Benign parathyroid lesions can be identified and located using morphological or functional imaging. Neck ultrasonography (US), computed tomography (CT) and magnetic resonance imaging (MRI) have been extensively used in this setting. Dual-tracer subtraction, mainly using 99mTc-sestamibi (MIBI)/99mTc-pertechnetate scans, and/or dual-phase scintigraphy with planar acquisitions, have been widely employed in cases of hyperparathyroidism, frequently combined with US. For diagnostic purposes, single-photon emission tomography (SPET)/CT has proved the best imaging modality for identifying the site of hyperfunctioning parathyroid glands, better than either SPET alone or planar scintigraphy. That said, even SPET/CT fails to identify the gland in up 30% of cases \[[@CR7]\].

When a combination of US and SPET/CT fails, a more effective imaging technique is needed. Radiolabeled choline PET/CT has been widely used in patients with recurrent prostate cancer \[[@CR8]\], and it was in this context that a study published in 2013 reported incidentally detecting an 18F-fluorocholine (FCH) hotspot in a patient's neck, which turned out to be a parathyroid adenoma \[[@CR9]\]. In the ensuing 6 years, a number of published studies reported on the role of FCH PET/CT in identifying benign parathyroid lesions.

The aims of the present systematic review are to: (1) assess the role of FCH PET/CT and PET/MRI in patients with known PHPT; and (2) compare the diagnostic performance of FCH PET/CT or PET/MRI with other morphological and/or functional imaging modalities.

Materials and methods {#Sec2}
=====================

Search strategy and study selection {#Sec3}
-----------------------------------

A literature search until December 2019 was performed in the PubMed, Scopus and Web of Science databases. The terms used were: "choline" AND "PET" AND "hyperparathyroidism". The search was run with and without the addition of filters, such as language (English only), type of article (original article), subjects (humans only), and only considering articles published in the last 5 years. Two reviewers (I.R., F.M.) conducted the literature search, and two independent physicians (L.E., D.C.) selected studies for inclusion, and data extraction. Any discrepancy was resolved by consensus. Independently identified records were combined, then the full texts were retrieved and examined by three reviewers (I.R., F.M., L.E.). The reference lists of the selected studies were carefully checked to identify any additional relevant literature.

A systematic review was conducted using established methods \[[@CR10]\], and the results are presented according to the PRISMA guidelines \[[@CR11]\].

Only studies that met the following inclusion criteria were considered eligible for the systematic review: (a) a sample size of more than 10 patients; and (b) FCH PET/CT as the index test. Clinical reports, conference abstracts, and editors' comments were excluded. Systematic reviews, with or without meta-analyses, were considered for the purpose of enriching the bibliographic references.

Data extraction {#Sec4}
---------------

For each study considered, the general information retrieved included: basic data (authors, year of publication, country, and study design); population characteristics (number of patients, type of hyperparathyroidism, PTH levels); the diagnostic reference standard; and the comparison of FCH PET/CT with other imaging modalities (i.e., US, 99mTc-MIBI SPET, or SPET/CT).

Statistical analysis {#Sec5}
--------------------

Continuous variables were expressed as median (range) and categorical as number (percentage). Data about diagnostic accuracies were obtained from each study to prepare a 2 × 2 contingency table and thus calculating the pooled sensitivity, by a patient-based and lesion-based analysis. Comprehensive meta-analysis (CMA) software version 3.3.070 (Biostat, Englewood, NJ, USA) was used for the assessment of pooled diagnostic performances.

Results {#Sec6}
=======

The systematic literature search generated 23 articles (see Fig. [1](#Fig1){ref-type="fig"}) concerning a total of 1112 patients investigated with FCH PET/CT for the detection of benign parathyroid lesions. Most of the studies were prospective (*n* = 15, 65%; 488 patients). Interestingly, 67 patients underwent FCH PET/MRI. As shown in Table [1](#Tab1){ref-type="table"} \[[@CR12]--[@CR33]\], FCH PET/CT was compared in many cases with US or 99mTc-MIBI scanning, the main endpoint being to assess the accuracy of FCH PET/CT in detecting benign parathyroid lesions in cases of doubtful or negative conventional imaging. In all studies, histopathological examination was the diagnostic reference standard.Fig. 1PRISMA flow for the selected studiesTable 1Summary of selected studies ordered by acquisition type (Dynamic or static with single or double time points) and year of publicationAuthors, refYear pubCountryN of ptsStudy designPTH level\
Median (range)\
Mean ± SDType of parathyroid diseaseProtocol FCH PET (dosage)End-pointComparison with other modalitiesOutcome*Dynamic studies*Michaud et al. \[[@CR12]\]2014France12P39.4 (4--176) ng/mLPHPT and SHPTDyn.10 min + Stat. (3 MBq/kg)To check if FCH uptake was a general feature of adenomatous or hyperplastic parathyroid glandsUS and/or 123I/MIBI dual-phase scintigraphyPTH decrease from 60 to 95%.Michaud et al. \[[@CR13]\]2015France17P280 (61--1946) pg/mLPHPT and SHPTDyn. 10 min (no activity data)To compare FCH-PET/CT findings in pts with discordant or equivocal results at US and scintigraphyUS and/or I123 + MIBI scintigraphyFCH-PET/CT sensitivity is better than that of US and not inferior to that of dual-phase I123 + sestaMIBI scintigraphyKluijhout et al. \[[@CR14]\]2017US10P86 ± 43 ng/mLPHPTDyn. 40 min (no activity data)To investigate the performance of FCH PET/MR imaging in patients with HP and non-localized disease who have negative or inconclusive results at US and MIBI scintigraphyUS, MIBI SPET/CTFCH PET/MR imaging allowed localization of adenomas with high accuracy when conventional imaging results were inconclusive and provided detailed anatomic information.Prabhu et al. \[[@CR15]\]2018India14PNAPHPT and PTADyn. 15 min + Stat. 45-60 min (185-296 MBq)To assess the utility of early dynamic FCH PET/CT in detecting parathyroid lesions and differentiating parathyroid lesions from cervical lymph nodesNoneEarly dynamic FCH PET/CT can detect parathyroid adenomas in PHPT*Static studies (single time point)*Kluifhout et al. \[[@CR16]\]2016The Netherlands44RNAHPT (MEN 1 and hyperpl.)Stat. 30 min (2 MBq/Kg)FCH PET/CT performance as second line imaging scanNoneFCH PET/CT is able to identify a HPT in case of inconclusive US and sestamibiQuak et al. \[[@CR17]\]2017France25P94.8 ± 37.4 ng/mLPHPT and PTAStat. 60 min (1.5 MBq/kg)Evaluate the sensitivity of FCH PET/CT for PTA detection prior to surgery in patients with PHPT and negative or inconclusive cervical ultrasound and MIBI SPET/CTUS and MIBI SPET/CT88% patients were considered cured after surgeryGrimaldi et al. \[[@CR18]\]2018France27P102.5 (59.0-514.0) ng/mLPHPTStat. 30 min (100 MBq)To evaluate the added value of pre-surgical FCH-PET/CT in localizing hyperfunctioning parathyroid glandsUS, MIBI + Tc SPET/CTFCH-PET/CT is a promising modality in challenging pre-surgical localizationHuber et al. \[[@CR19]\]2018Switzerland26R110.8 (54.9-257.6) ng/mLPHPTStat. 10 min (150 MBq)FCH-PET/CT or MRI ability to pre-surgical localization of PT in case of negative or conflicting US and scintigraphyUS, I123 + Tetrofosmin SPET/CTFCH-PET is a highly accurate method to detect PT adenomas even in case of failure of other imaging examinationsAraz et al. \[[@CR20]\]2018Turkey35P123.06 ± 34.82 ng/mLPHPTStat. 45-60 min (100 MBq)Comparison between FCH PET/CT and MIBI SPET/CT in hyperparathyroidism and the utility of SUVmax for the evaluation of disease severityMIBI SPET/CTFCH has a higher performance than MIBI SPECT/CT. SUV is correlated with PTH and bone mineral densitometry (BMD) scoresPiccardo et al. \[[@CR21]\]2018Italy44P120.7 (71.8--545) ng/mLPHPTStat. 10 min (100 MBq)Comparison among integrated FCH-PET/4DCeCT and FCH-PET/CT and 4DCeCT detection rate and sensitivity4DCeCTIntegrated FCH-PET/4DCeCT has a performance superior to that of FCH-PET/CT and 4DCeCT, separatelyZajickova et al. \[[@CR22]\]2018Czech Republic13P114.6 (78.9--145) ng/mLPHPTStat. 30 ± 20 min (180 MBq)FCH PET/CT was performed after inconclusive neck US and MIBI SPET scintigraphy in patients with PHPT to localize abnormal parathyroid glands before surgeryUS and MIBI scintigraphyFCH correctly identified PTA and hyperplastic glands in 92% patients with previously inconclusive conventional imagingFischli et al. \[[@CR23]\]2018Switzerland39R168.39 ± 110.69 ng/mLPHPTStat. 45 min (160 MBq)To evaluate the sensitivity and specificity of FCH-PET/CT for preoperative localization in patients with pHPT and negative or equivocal 99mTc-sestamibi scintigraphy and/or ultrasoundNoneFCH-PET/CT provides an excellent sensitivity of \> 90% per-patient and of \> 87% per lesion-based levelAmadou et al. \[[@CR4]\]2019France29R122.81 ± 50.78 ng/mLPHPTStat. 60 min (230 MBq)To evaluate FCH-PET/CT and parathyroid 4D-CT as to guide surgery in patients with PHPT and prior neck surgeryUS, MIBI scintigraphy and/or MIBI SPET/CT, 4D-CTSuperiority of FCH-PET/CT and 4D-CT compared to first-line imaging in re-operative patients***Static studies (Dual Time Point):***Lezaic et al. \[[@CR24]\]2014Slovenia24PNAPHPTStat. 5 and 60 min (100 MBq)Evaluate the usefulness of FCH PET/CT for preoperative localization of hyperfunctioning parathyroid tissueMIBI SPET/CT, MIBI dual-phase and MIBI/Tc subtraction imagingFCH PET/CT appears to be a promising, effective imaging method for localization of hyperfunctioning parathyroid tissueRep et al. \[[@CR25]\]2015Slovenia43P311.5 (70.6--2022) ng/mLPHPTStat 5, 60 and 120 min (100 MBq)To determine the optimal scan time, i.e., time between radiopharmaceutical administration and FCH PET/CT imaging in patients with a PHPTConventional MIBI scanOptimal imaging time is one hour after the administration of FCHHocevar et al. \[[@CR26]\]2016Slovenia151RNAPTAStat. 5 and 60 min (100 MBq)To analyze the results of FCH-PET/CT pre-surgical localization and the possibility to skip ioPTH testing in pts with single adenomaUS, MIBI SPECT/CTFCH-PET/CT is a reliable test in pre-surgical localization and pts with single PTA on PET can safely undergo a focused parathyroidectomyRep et al. \[[@CR27]\]2018Slovenia36PNAPHPTStat. 5 and 60 min (100 MBq)To measure the organ doses and the ED for conventional subtraction parathyroid imaging protocols, using dual-phase MIBI SPET/CT as a potential conventional imaging method of choice and FCH dual-phase PET/CT as a potential future imaging method of choice for localisation of HPGsParathyroid subtraction scintigraphy and dual-phase SPET/CTIn HPGs, SPET/CT and PET/CT have a superior diagnostic performance than conventional scintigraphyAlharbi et al. \[[@CR28]\]2018Switzerland52R122.4 ± 49.9 ng/mLPTA (only single adenomas)Stat. 2 and 50 min (150 MBq)To investigate the relationship between FCH-PET (MR and CT) results and PTH levelsNoneFCH uptake in PTA is strongly correlated with preoperative PTH serum levelsBeheshti et al. \[[@CR29]\]2018Austria100P196.5 ± 236.4 pg/mLPTAStat. 60 and 120 min (3.2 MBq/Kg)To compare assessment of PHPT from FCH-PET/CT and MIBI or Tetrofosmin SPECT/CTMIBI or Tetrofosmin SPECT/CTFCH-PET/CT is clearly superior to MIBI/Tetrofosmin SPET/CT in detecting PTA, especially small onesBossert et al. \[[@CR30]\]2018Italy34P179.9 ± 123.1 ng/mL (Hypercalcemic) 158.4 ± 55.4 ng/mL (Normocalcemic)PTAStat. 9 and 60 min (3.5 MBq/Kg MBq)To compare diagnostic performance of FCH-PET/CT with MIBI + TC SPET/CTUS, MIBI + TC SPET/CTFCH-PET/CT can be considered a first line imaging technique in pts with normo- or hypercalcemic PHTPChristakis et al. \[[@CR31]\]2019UK12R19.1 ± 5.11 ng/mLPHPT or recurrent PTAStat. 60 and 90 min (300 MBq)To assess if FCH PET/CT is able to identify parathyroid adenomas, with a negative scanNoneFCH PET/CT is able to identify the presence of adenoma parathyroid also in case of negative conventional imagingThanseer et al. \[[@CR32]\]2019India54P165.5 (117--362.5) ng/mL in eutopic 302 (236--1264) ng/mL in ectopicPHPTStat. 10-15 min + 60 min (150-185 MBq)to compare pre-surgery localization in US, MIBI SPECT/CT and FCH PETUS, MIBI SPECT/CTFCH PET/CT has higher sensitivity and specificity especially in patients with small and ectopic PHPT and low, slight PTH valuesBroos et al. \[[@CR33]\]2019The Netherlands271R16.1 ± 11.3 ng/mLPHPTStat. 5 and 60 min (150 MBq)To evaluate FCH PET/CT as a first-line modalityNoneHigh detection rates of FCH PET/CT in PHPT. FCH PET/CT can be used as a first-line imaging modality in preoperative planning of parathyroid surgery*SD* standard deviation, *PHPT* primary hyperparathyroidism, *SHPT* secondary hyperparathyroidism, *PTA* parathyroid adenoma, *Stat*. Static acquisition, *Dyn*. Dynamic acquisition, *P* Prospective study, *R* Retrospective study, *NA* not available

A careful analysis of the selected literature showed that a dynamic FCH PET/CT protocol was used in 4/23 studies. In particular, Michaud et al. \[[@CR13]\] and Kluijhout et al. \[[@CR14]\] ran a single dynamic acquisition lasting 10 min and 40 min, respectively; and Michaud et al. and Prabhu et al. \[[@CR12], [@CR15]\] performed a dynamic acquisition for 10-15 min followed by a static image 10 or 45 min after the injection. Static acquisitions were obtained in the other studies at a single point ranging from 10 to 60 min after the intravenous administration of FCH in 9/23 studies \[[@CR4], [@CR16], [@CR17], [@CR19]--[@CR23], [@CR34]\]; and twice, first after 2--60 min and then after 60--120 min, in 10/23 studies. Only Rep et al. \[[@CR25]\] reported scanning patients 3 times, at 5, 60 and 120 min after FCH injection. The FCH dosage was fixed in 16 studies, in the range of 100-230 MBq \[[@CR15], [@CR19]--[@CR28], [@CR31]--[@CR34]\]; it was adjusted to the patient's body weight in 5 (1.5--3.2 MBq/kg) and not declared in two studies \[[@CR12], [@CR16], [@CR17], [@CR29], [@CR30]\].

FCH PET/CT was compared with US by Amadou et al. \[[@CR4]\], Bossert et al. \[[@CR30]\], Hocevar et al. \[[@CR26]\], Michaud et al. \[[@CR13]\], and Thanseer et al. \[[@CR32]\]. FCH PET/CT proved to be superior to US in detecting benign parathyroid lesions, with a sensitivity in the range of 85.2--100% and 50--82%, respectively, on patient-based and lesion-based analysis.

Comparisons between FCH PET/CT and 99mTc-MIBI SPET/CT with a dual-phase and/or subtraction protocol were reported in numerous studies (Table [2](#Tab2){ref-type="table"}; \[[@CR4], [@CR12]--[@CR17], [@CR19]--[@CR34]\]).Table 2Comparative performance of FCH PET/CT or PET/MRI Vs conventional imaging modalities ordered by acquisition type (Dynamic or static with single or double time points) and year of publicationAuthors, refStand. of ref.FCH PET/CTComparative imagingSENS.SPEC.PPVNPVACC.SENS.S SPEC.PPVNPVACC.*Dynamic studies*Michaud et al. \[[@CR12]\]Histology89% (PL)94% (PL)Michaud et al. \[[@CR13]\]Histology94% (PP)96% (PL)both in masked and open readingPL:88% (open)56% (masked)----PL:94% (open)85% (masked)US:50% (PP)50% (PL)I123 + SestaMIBI:94% (PP)83% (PL) both in masked and open readingPL:33% (US)56% (I123 + SestaMIBI) both in masked and open reading----PL:46% (US)76%(I123 + SestaMIBI) both in masked and open readingKluijhout et al. \[[@CR14]\]Histology90%100%Prabhu et al. \[[@CR15]\]Histology--------------------*Static studies (single time point)*Klujfhout et al. \[[@CR16]\]Histology97.1%--97.1%--97.1%----------Quak et al. \[[@CR17]\]Histology91.3% (PL)90.5% (PP)--87.5% (PL)86.4% (PP)--80.7% (PL)----------Grimaldi et al. \[[@CR18]\]Histology and follow up81% (PP)76% (PL)--91% (PL)94% (PP)85% (PL)--86% (PL)--------------Huber et al. \[[@CR19]\]Histology and biochemistry96.2% (PP)--100% (PL)--------------Araz et al. \[[@CR20]\]Follow-up and histology96%100%100%93%97%78%100%100%70%86%Piccardo et al. \[[@CR21]\]Histology, biochemistry and follow up81% (PL)--------PL:54.5% (4DCeCT)100% (PET + 4DCeCT)--------Zajickova et al. \[[@CR22]\]Histology92%100%92%Fischli et al. \[[@CR23]\]Histology95.5% (PP)87.5% (PL)------------------Amadou et al. \[[@CR4]\]Histology and follow up85.2% (PP)95.8% (PL)12.5% (PL)76.7% (PL)50% (PL)--PL:54.2% (US)50% (MIBI)75% (4D-CT)PL:75% (US)75% (MIBI)40 (4D-CT)PL:86.7% (US)85.7% (MIBI)80% (4D-CT)PL:35.3% (US)33.3% (MIBI)33.3% (4D-CT)--*Static studies (dual time point)*Lezaic et al. \[[@CR24]\]Histology92%100%100%96%98%49% (MIBI SPET/CT)46% (MIBI-Tc)44% (MIBI dual-phase)100% (MIBI SPET/CT, MIBI-Tc and MIBI dual-phase)100%80%83%Rep et al. \[[@CR25]\]Histology90.5% (5 min)93.6% (1 h)93.6% (2 h)95.3% (all)98.2% (5 min)98.2% (1 h)98.2% (2 h)98.2% (all)96.6% (5 min)96.7% (1 h)96.7% (2 h)96.8% (all)94.7% (5 min)96.4% (1 h)96.4% (2 h)97.3% (all)94.1% (5 min)96.5% (1 h)96.5% (2 h)97% (all)----------Hocevar et al. \[[@CR26]\]Histology and biochemistry----95.2% (PL)96.8% (per single PTA)----61% (US per single PTA)62% (MIBI-SPET/CT per single PTA)--------Rep et al. \[[@CR27]\]Histology97%99%46% (PSS), 64% (SPET/CT)98% (PSS), 96% (SPET/CT)Alharbi et al. \[[@CR28]\]PET positivity and histology--------------------Beheshti et al. \[[@CR29]\]Histology and follow up93.7% (PL)96% (PL)90.2% (PL)97.4% (PL)95.3% (PL)60.8% (PL)98.5% (PL)94.1% (PL)86.3% (PL)87.7% (PL)Bossert et al. \[[@CR30]\]Histology or citology/biochemistry88%--------82% (US)17% (Tc + MIBI SPET/CT)--------Christakis et al. \[[@CR31]\]histology58.3%----100%58.3%----------Thanseer et al. \[[@CR32]\]Histology100% (PP)100% (PL)----96.3% (PP)92.8% (PL)----96.3% (per pts)92.8% (PL)MIBI SPECT/CT 80.7% (PP)76.4% (PL)US 69.3% (PP)69.3% (PL)MIBI SPECT/CT 100% (PP)75% (PL)US 29% (PL)MIBI SPECT/CT 97.7% (PP)97.7% (PL)US 87.1% (PP)87.1% (PL)MIBI SPECT/CT 9% (PP)23% (PL)US12% (PL)MIBI SPECT/CT 79.6% (PP)80.4% (PL)US 62.9% (PP)64.3% (PL)Broos et al. \[[@CR33]\]Histology96% (PP)90% (PL)100%96% (PP) 90% (PL)*SENS*. sensitivity, *SPEC*. specificity, *ACC*. accuracy, *PP* per patient, *PL* per lesion

Quak et al. \[[@CR17]\], Araz et al. \[[@CR20]\], Kluijhout et al. \[[@CR16]\], Hocevar et al. \[[@CR26]\], and Thanseer et al. \[[@CR32]\] found FCH PET/CT more sensitive than dual-phase SPET/CT (100% vs. 80.7%, and 100% vs. 76.4%, respectively, for patient-based and lesion-based analyses).

Michaud et al. \[[@CR12], [@CR13]\], Lezaic et al. \[[@CR24]\], Zajickova et al. \[[@CR22]\], Rep et al. \[[@CR27]\], Amadou et al. \[[@CR4]\], Beheshti et al. \[[@CR29]\], Bossert et al. \[[@CR30]\], Grimaldi et al. \[[@CR34]\], and Huber et al. \[[@CR19]\] compared FCH PET/CT with 99mTc-MIBI/99mTc-tetrofosmin SPET/CT performed with both subtraction and dual-phase protocols. They found FCH PET/CT superior to SPET/CT with the subtraction and dual-phase protocols for the detection of adenoma and/or hyperplastic parathyroid, with a diagnostic accuracy of 97.4% and 87.7% for PET/CT and SPET/CT, respectively, on lesion-based analyses.

In the study by Kluijhout et al. \[[@CR14]\], 10 patients were studied with FCH PET and MRI, and compared with the same patients examined using US and a dual-phase 99mTc-MIBI SPET/CT. While for PET/MRI the sensitivity was 90% and the positive predictive value (PPV) was 100%, MRI alone showed a sensitivity of 55.6% and a PPV of 83.3%. In Fig. [2](#Fig2){ref-type="fig"} is reported a 65-year-old patient with persistent hyperparathyroidism after surgery who underwent FCH PET/MRI in our Department.Fig. 2Example of positive 18F-FCH PET/MRI (Biograph mMR, Siemens Germany) and negative 99MTc-MIBI SPECT/CT (Infinia Hawkeye, GE Healthcare) performed at the University Hospital of Padova, Department of Medicine, Unit of Nuclear Medicine in a patient with hyperparathyroidism after left thyroidectomy (during a surgical procedure of left parathyroidectomy). MR axial Caipirinha in-phase (1) and MR axial Caipirinha out of-phase (2) demonstrating an ovoidal mass (red arrows) partially liquid at axial T2-Haste (3) with a very high posterior, paratracheal uptake of 18F-FCH PET/MR (4, red arrow). 99MTc-MIBI early after injection (5) and late after injection (6) phases of the same patient demonstrating no significant late retention of MIBI in the area revealed by 18F-FCH PET/MRI. SPET/CT of the same patient revealed only faint uptake (7: red cross) of MIBI in the paratracheal area revealed by 18F-FCH PET comparable to the background

True positive, false positive, true negative and false positive were available in 18 studies, at patient-based analysis and in 14 studies at lesion-based analysis (Table [3](#Tab3){ref-type="table"}). Totally, true positive findings were reported in 686 patients and 530 lesions, respectively. Conversely, the number of false negative results were 35 and 23 on patient-based and lesion-based analysis. Pooled sensitivities were 93.7% and 91.3%, on patient-based and lesion-based analysis, respectively, as illustrated in Fig. [3](#Fig3){ref-type="fig"}.Table 3Diagnostic data of FCH PET/CT or PET/MRI, based on patient-based and lesion-based analysisAuthors, refYear\
publ.Patient-based analysisLesion-based analysis*N*TPTNFPFN*N*TPTNFPFNMichaud et al. \[[@CR12]\]201412110012017012Lezaic et al. \[[@CR24]\]201424230013936003Michaud et al. \[[@CR13]\]201516150012523011Klujfhout et al. \[[@CR16]\]201633300123533110Kluijhout et al. \[\[[@CR14]\]2017109001----------Fischli et al. \[[@CR23]\]201723210112921413Hocevar et al. \[[@CR26]\]2017151144142----------Thanseer et al. \[[@CR32]\]201754520205854040Quak et al. \[[@CR17]\]201824190322621032Grimaldi et al. \[[@CR18]\]2018211701376224347Huber et al. \[[@CR19]\]201826250012827001Zajickova et al. \[[@CR22]\]20181311011----------Rep et al. \[[@CR25]\]20181443910311----------Beheshti et al. \[[@CR29]\]201882763032777419085Piccardo et al. \[[@CR21]\]201931250063131000Amadou et al. \[[@CR4]\]201925231013223171Bossert et al. \[[@CR30]\]201917150021715002Broos et al. \[[@CR33]\]20191371310061481330015*TP* true positive, *TN* true negative, *FP* false positive, *FN* false negativeFig. 3Forest plots for pooled sensitivities of FCH PET/CT or PET/MRI per patient-based and lesion-based analysis

Discussion {#Sec7}
==========

The present systematic review showed that, in a population with negative/doubtful imaging findings, FCH PET/CT is more accurate than 99mTc-MIBI scintigraphy (whatever the protocol used) and US in patients with primary or recurrent hyperparathyroidism (all 23 studies considered in the review had included patients with primary hyperparathyroidism, and two (Amadou et al. \[[@CR4]\] and Christakis et al. \[[@CR31]\]) also included cases of recurrent hyperparathyroidism.

It is important to bear in mind that acquisition protocols for FCH PET/CT vary considerably. This can have an important impact on how images are interpreted and could bias their reported accuracy. FCH PET/CT was nonetheless superior to conventional scintigraphic or radiological approaches in most cases, regardless of the protocol used. In the majority of the studies considered, a single static acquisition was obtained at any time between 2 and 60 min after injecting the tracer. In 6/8 studies involving single static acquisitions, this interval ranged between 30 and 60 min. Full dynamic analysis could clarify the best timing of a static acquisition more precisely. This aspect does not seem to have been addressed in the literature to date and could be an interesting topic for future research. Only the paper by Prabhu et al. \[[@CR15]\] reported the time active curves for parathyroid adenoma, thyroid gland and lymph node, demonstrating a higher uptake in parathyroid adenoma in the first 5 min after tracer injection. Michaud et al. \[[@CR13]\] demonstrated that abnormal foci at a parathyroid gland were visible on early images, although the significant uptake in blood vessels imposed a more careful analysis of the cross-sectional images. Rep et al. \[[@CR25]\] reported a slightly higher accuracy and sensitivity on scans obtained after 60 min than on those obtained after 5 min (94.1 vs. 96.5% and 90.5 vs. 93.6%, respectively). They consequently suggested that, for the preoperative localization of parathyroid gland, image acquisition was optimal 1 h after administering FCH.

Eight studies reported false positive results and 17 obtained false negative findings at 18F-Choline PET/CT (see Table [3](#Tab3){ref-type="table"}), in accordance with the patient-based analysis. False-positive and false-negative results were frequently due to misinterpretation of thyroid anomalies, or due to a high uptake in normal or hyperplastic parathyroid glands, or in case of ectopic glands or adenomas with no specific characteristics or in case of very small adenomas with a fairly low number of oxyphilic cells.

As in the case of 99mTc-MIBI SPET/CT, some authors preferred to use a dual-phase FCH PET protocol (PET/CT or PET/MRI). It should be noted, however, that the kinetic characteristics of radiolabeled choline are very different from those of 99mTc-MIBI, and so the proper timing of the former cannot be deduced directly from the latter. 99mTc-MIBI accumulates more intensely in malignant cells because of their higher mitochondrial density and transmembrane electrical potential. Non-specific mechanisms lead to the uptake in nontumor cells with a greater metabolic activity or higher density of mitochondria---a situation encountered in atypical hyperplasia or particularly active tumor-like granulation. 99mTc-MIBI uptake in parathyroid foci was found to depend not on the cell type, but rather on either the size or the functional state of a lesion (Fukumoto et al. \[[@CR35]\]). On the other hand, tumor cells with a high proliferation rate will have a high uptake of FCH to keep up with an increased demand for the synthesis of phospholipids (Vallabhajosula et al. \[[@CR36]\]). A possible explanation for FCH uptake in benign parathyroid adenomas seems to be the increase in phospholipid-dependent choline kinase activity arising from PTH hypersecretion (Ishizuka et al. \[[@CR37]\]).

A number of systematic reviews and meta-analyses on FCH PET/CT have been published in the last 2 years (Table [4](#Tab4){ref-type="table"}) (Kim et al. \[[@CR38]\]; Treglia et al. \[[@CR39]\]; Boccalatte et al. \[[@CR40]\]; Broos et al. \[[@CR33]\]). In all cases, FCH PET/CT had an optimal performance in identifying benign parathyroid lesions. To the best of our knowledge, however, our systematic review is the first to include a large number of studies (*n* = 23), and to compare FCH PET/CT with conventional imaging (US and 99mTc-MIBI scanning), based on per-patient and per-lesion analyses. The present review also paid attention to the timing of image acquisition. In clinical practice, it seems that FCH PET/CT could be used for localizing and identifying benign parathyroid lesions, irrespective of the severity of PHPT (Beheshti et al. \[[@CR29]\]), and particularly in patients with equivocal or negative conventional imaging.Table 4Summary of the published English systematic reviews about 18F-Choline PET/CT in hyperparathyroidismAuthors, refYear of pubMeta-analysisN of included studiesComparison with other imagingOutcomeKim et al. \[[@CR38]\]2018Yes8No18F-Choline PET has a pooled sensitivity of 90% and a pooled specificity of 94% for the identification of HPTTreglia et al. \[[@CR39]\]2019Yes18NoRadiolabeled Choline PET has a pooled sensitivity of 95% and a pooled PPV of 91% for the identification of HPTBoccalatte et al. \[[@CR40]\]2019No15No18F-Choline PET provides a high accuracy, sensitivity and specificity for the identification of HPTBroos et al. \[[@CR33]\]2019No11NoHigh detection rate of choline PET/CT in preoperative localization of hyperfunctioning parathyroid glands in patients with primary HPT

CT and MRI have always had a marginal role in parathyroid imaging, and been applied mainly when the results of US and 99mTc-MIBI are difficult to interpret, or when parathyroidectomy fails due to ectopic glands (Johnson et al. \[[@CR41]\]). Recent technical advances enabling high-resolution MRI of the neck have increased the applicability of such techniques, however. Even small lesions can be reliably detected and characterized nowadays on conventional sequences or with methods like diffusion weighted imaging (DWI) (Yildiz et al. \[[@CR42]\]). 4DCeCT combines standard multiplanar CT scanning (non-contrast, arterial and venous phases) with the fourth dimension of changes in contrast attenuation over time, providing both functional and anatomical information about the abnormal parathyroid gland. Some recent studies have reported the role of 4DCeCT in patients with persistent or recurrent parathyroid hyperfunction, showing a sensitivity until to 86% \[[@CR43]--[@CR46]\]. Piccardo et al. \[[@CR21]\], showed that in 31 patients, the association of 18F-Choline PET with 4DCeCT could enhance the sensitivity to 100% in patients with persistent or recurrent hyperfunctioning parathyroid.

Argiro' et al. \[[@CR47]\], for instance, found MRI more sensitive (97.8%) than US or 99mTc-MIBI, either alone (89.1% and 83.6%, respectively) or combined (93.4%), for the pre-surgical detection of benign parathyroid lesions, as well as for the diagnosis of multiglandular disease and ectopic parathyroid adenomas.

Yildiz et al. \[[@CR48]\] demonstrated that DWI enables solid parathyroid lesions to be distinguished from surrounding structures, and can also detect different types of lesions with peculiar MRI characteristics on T1w and T2w sequences. They found that parathyroid adenoma and hyperplasia usually appear as small lesions with well-defined margins and contrast enhancement, while parathyroid carcinomas are larger and less homogeneous.

Finally, in a recent study, Ozturk et al. \[[@CR44]\] correctly localized 38 parathyroid lesions using 4D MRI, reporting a sensitivity of 90.5% and a PPV of 95%.

The advantages and disadvantages of all imaging techniques that can be used in the definition of parathyroid benign lesions are listed in Table [5](#Tab5){ref-type="table"}.Table 5Pros and Cons of different imaging techniques used for parathyroid benign lesionsImaging techniqueProsConsUSNo radiation exposureWidely available, cost effectiveDoppler can assist in distinguishing parathyroid lesions from other surrounding structures: identification of polar arteries of parathyroid glands vs. hilar blood supply of lymph nodesConcurrent assessment of the thyroid and possibility of performing percutaneous biopsiesOperator dependentAccuracy can be limited in patients with elevated body mass indexVisualization of low inferior glands can be particularly difficult in patients unable to extend their neckDifficult detection of ectopic glands located in the mediastinumMIBI SPECTWidely available, cost effectiveConsolidated protocols described, including single-tracer double phase and dual-tracer single phase imagingPossibility of detecting ectopic lesions, particularly if in mediastinumThyroid nodules, thyroiditis and enlarged cervical lymph nodes may have delayed tracer washout and give the appearance of a thyroid adenomaLong acquisition time, compliance of patients is requiredIntermediate radiation dose (7--11 mSv)4D-ceCTCharacterization of lesion enhancement could offer insights into the benign/malignant nature of the parathyroid lesion/sExcellent anatomic detail and possibility of detecting ectopic lesionsHigh radiation dose (10--27 mSv)MRICharacterization of lesion enhancement could offer insights into the benign/malignant nature of the parathyroid lesion/sExcellent anatomic detail and possibility of detecting ectopic lesionsNo radiation exposureLong acquisition time, compliance of patients is requiredHigh costs and limited availability18F-Choline PET/CT and PET/MRGreater spatial resolution than MIBI SPECT and shorter image acquisition timeLack of protocol standardization (optimal imaging timing, dynamic acquisition, administered activity etc.)Currently not clinically approvedHigh costs and limited availability

In the light of the above, an approach combining FCH PET with MRI (using PET/MRI scanners or PET/CT with MRI) represents an optimal choice, improving on the accuracy of either method. Unfortunately, the paucity of data on PET/MRI in this field prevents us from drawing any further conclusions about the diagnostic potential of this technique.

Conclusions {#Sec8}
===========

FCH PET is more accurate than conventional imaging modalities (US and 99mTc-MIBI SPET/CT, whatever the protocol used) in detecting benign parathyroid lesions. It has a potential role in both primary and recurrent hyperparathyroidism. Although it would be necessary to conduct a cost-effective analysis before adopting this imaging modality in clinical practice, it seems important to emphasize that, in selected cases, when the outcome of conventional US and scintigraphy is hard to interpret, FCH PET is an appropriate choice. PET/MRI is a very promising technique in this field, but further research is needed to fully assess its role.
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